Investors and Media

Idera is advancing to the clinic in autoimmune diseases and certain genetically defined forms of B-cell lymphoma: activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia and others. Its lead drug candidate, IMO-8400, is designed to modulate immune responses through Toll-like receptors (TLRs).

Recent News

Jan 04, 2017Idera to Present at the 35th Annual J.P. Morgan Healthcare ConferenceRead MoreNov 28, 2016Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200Read MoreNov 11, 2016Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 TreatmentRead More

Upcoming Events

There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.